ARPA‑H awarded BioCurie up to $9.3 million to build an AI‑driven, data‑centric platform for scalable gene‑therapy manufacturing. The program seeks to replace trial‑and‑error process development with computational modeling and machine learning to reduce timelines and de‑risk production of viral and non‑viral genomic medicines. BioCurie will coordinate a consortium including Caring Cross, St. Jude Children’s Research Hospital, and the Center for Breakthrough Medicines to validate the platform across manufacturing steps. ARPA‑H program manager Daria Fedyukina will oversee the project. If successful, the platform could compress process development cycles, improve robustness, and lower costs—addressing a major industrial bottleneck that limits patient access to curative genomic therapies.